InsidersTradesSigma
Total declarations
Companies
▲ Purchases (4 ops.)
▼ Sales (0 ops.)
Insider track record
ExecutiveDisclosed buys
4
Disclosed sells
0
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
Signal history
Explore the detailed record of transactions filed by Kenney Richard T, Directeur Médical. Director active across 2 companies, notably Sonnet BioTherapeutics Holdings, Inc.. Cumulatively, 8 filings have been published. Breakdown: 4 buys · 0 sell. Total volume traded: €63k. Activity tracked since 19 May 2021. The latest transaction was disclosed on 9 June 2021 (Acquisition). Regulator: SEC (Form 4). All data is free.
Declarations8 total
1,271 sharesCommon StockSEC:0001493152-24-048953:0
14,627 sharesCommon StockSEC:0001493152-23-005469:0
14,627 sharesCommon StockSEC:0001493152-22-036312:0
15,000 shares@ US$1.5429.9% of flowCommon StockSEC:0001493152-21-013939:0
Ideal exit: 6 Mar 2022 (T+270)
15,000 shares@ US$1.5429.9% of flowCommon StockSEC:0001493152-21-013939
Ideal exit: 6 Mar 2022 (T+270)
10,000 shares@ US$1.5520.1% of flowCommon StockSEC:0000905718-21-000714
Ideal exit: 13 Feb 2022 (T+270)
10,000 shares@ US$1.5520.1% of flowCommon StockSEC:0000905718-21-000714:0
Ideal exit: 13 Feb 2022 (T+270)
7,000 sharesCommon StockSEC:0001123292-16-001535:0
8 of 8 declarations
About Kenney Richard T
Richard T. Kenney is the Chief Medical Officer at Sonnet BioTherapeutics Holdings, Inc. He oversees the company's medical and research initiatives, contributing to its development in the biopharmaceutical sector.
